Press release content from Globe Newswire. The AP news staff was not involved in its creation. Novadiscovery raises Series A2 financing from Sanofi to advance JINKO, its best-in-class ... NovadiscoveryFebruary 16, 2021 GMT NOVA to develop COVID-19 disease model to support Sanofi’s vaccine and therapeutic efforts Lyon, France – 16 February 2021: Novadiscovery (“NOVA”), a leading health tech company offering JINKO, a best-in-class clinical trial simulation platform to predict drug efficacy and optimize clinical trial development, today announces that it has raised €2.5 million in a Series A2 financing round from Sanofi. The funds will be used to advance NOVA’s in silico clinical trial simulation platform, JINKO; to facilitate the Company’s expansion into the US; and develop a COVID-19 disease model in collaboration with Sanofi. JINKO’s workflows are designed to closely resemble those of real life clinical studies and it offers an integrated suite of applications from Discovery to Market Access.